Multimodal evaluations including metabolic imaging and assessment of GCase activity, α-synuclein levels, and lipid and metabolic profile may shed light on inter-genotype differences, discover new biomarkers for clinical and research setting, and unveil novel mechanisms underlying GBA-PD pathogenesis. Here, GBA1 is linked to Parkinson disease.